A high HE4 result deserves careful follow-up, not an automatic cancer conclusion. The number only becomes useful when read alongside kidney function, menopausal status, imaging and the reason the test was ordered.
- High HE4 levels can occur with ovarian malignancy, but chronic kidney disease, smoking, age and some non-gynaecologic illnesses can also raise the result.
- Common assay cutoffs are about 70 pmol/L before menopause and 140 pmol/L after menopause, although laboratories and assay methods differ.
- Kidney function matters: HE4 rises as eGFR falls, so an elevated HE4 with eGFR below 60 mL/min/1.73 m² needs particularly cautious interpretation.
- ROMA score combines HE4, CA-125 and menopausal status for women with an adnexal mass who are being evaluated for surgery; it is not an ovarian-cancer screening test.
- No HE4 blood test can diagnose ovarian cancer alone; ultrasound or other imaging and specialist assessment determine the next step.
- A normal HE4 does not rule out ovarian cancer, especially early-stage disease or tumour types that produce little HE4.
- ອາການດ່ວນ include rapidly progressive abdominal swelling, severe pelvic pain, breathlessness, vomiting or reduced urine output.
- ແນວໂນ້ມ ແລະ ບໍລິບົດ usually matter more than one isolated HE4 value measured at a different laboratory or with a different assay.
What an elevated HE4 result means in plain language
An elevated HE4 result does not mean you have ovarian cancer. HE4 is a protein marker that can rise with certain ovarian cancers, but it also rises when kidney filtration is reduced and in several non-cancer settings. In my clinical experience, the first useful question is not “How high is it?” but “Why was it measured, and what do the creatinine, eGFR and scan show?”
HE4, also called WFDC2, is measured in picomoles per litre (pmol/L) and is mainly used when a clinician is assessing a pelvic or adnexal mass. A result above a laboratory flag is a signal to assess context, not a diagnosis. Dr. Thomas Klein, Kantesti’s Chief Medical Officer, has seen many anxious patients whose modest HE4 rise was explained by an eGFR of 45 mL/min/1.73 m² rather than cancer.
The clinical concern rises when high HE4 occurs alongside a suspicious pelvic ultrasound, a rising CA-125, persistent symptoms and a postmenopausal presentation. In contrast, HE4 of 95 pmol/L in a premenopausal person with stable imaging and reduced kidney function has a very different pre-test probability. Our CA-125 symptom guide explains why neither marker should be read in isolation.
ແຄນເທສຕີ ເປັນ AI ເຄື່ອງວິເຄາະເລືອດ that places HE4 beside renal markers, age, reported sex, menopausal status and the laboratory’s own reference interval. That structured comparison can identify a follow-up question; it cannot replace an examination, ultrasound or gynaecology referral.
The most useful first step
Ask for the exact HE4 value, unit, laboratory reference interval, creatinine, eGFR, CA-125, menopausal status and the indication for testing. Those seven details change the interpretation far more than a red “high” flag alone.
What the HE4 blood test measures and when doctors use it
The HE4 blood test measures a secreted protein called human epididymis protein 4, encoded by the WFDC2 gene. It is used primarily to help estimate malignancy risk in an existing adnexal mass, rather than to find cancer in healthy people without symptoms.
Laboratories measure HE4 using automated immunoassays, and the numbers are not perfectly interchangeable between manufacturers. A value of 80 pmol/L from one method should not be treated as identical to 80 pmol/L from another without checking the report. This is one reason a trend is most reliable when samples use the same laboratory and method.
HE4 is expressed in several normal tissues and may be overexpressed by many epithelial ovarian cancers, particularly serous and endometrioid types. It is less helpful for mucinous tumours and some early-stage cancers. A normal result therefore reduces neither symptoms nor imaging findings to “nothing.”
Kantesti’s ຄູ່ມືຕົວຊີ້ວັດຊີວະພາບໃນເລືອດ distinguishes a tumour marker from a diagnostic test: the former changes probability, while the latter may require imaging, histology and specialist review. That distinction prevents a surprisingly common misunderstanding after patient-portal results arrive before a clinician calls.
HE4 reference ranges: why 70 and 140 pmol/L are not universal
Many laboratories use HE4 cutoffs near 70 pmol/L before menopause and 140 pmol/L after menopause, but these are assay-specific decision thresholds rather than universal normal ranges. Your report’s stated reference interval takes precedence over an internet number.
The widely used 70 and 140 pmol/L thresholds arose from validation work for specific HE4 assays and risk algorithms. They are practical decision aids, not biologic cliffs. A result of 72 pmol/L is not meaningfully different from 68 pmol/L if sample variation, eGFR and assay uncertainty are considered.
Postmenopausal reference limits are higher partly because HE4 increases with age even without cancer. Some European laboratories use age-adjusted upper limits rather than one postmenopausal cutoff. When I review a value just above range, I want the actual age, renal indices and prior value before recommending any conclusion.
A laboratory high flag simply means the result exceeded that laboratory’s reference population. For a broader explanation of flags, see ຜົນທີ່ຢູ່ນອກຊ່ວງອ້າງອີງໝາຍຄວາມວ່າຢ່າງໃດ.
Why reduced kidney function can raise HE4 substantially
Reduced kidney filtration is one of the strongest non-cancer reasons for high HE4 levels. HE4 is cleared in part through the kidneys, so concentrations commonly rise as eGFR declines, sometimes well above standard postmenopausal cutoffs.
eGFR ຕໍ່າກວ່າ ສະແດງວ່າເປັນ CKD, ຕ່ຳກວ່າ persisting for 3 months meets the usual definition of chronic kidney disease, and this degree of reduction can materially distort HE4 interpretation. In advanced chronic kidney disease, HE4 may reach several hundred pmol/L without ovarian cancer. The relationship is strong enough that renal function should be on every HE4 request review.
Creatinine can be misleading in people with very low or very high muscle mass, dehydration or recent intense exercise. A 58-year-old patient with HE4 of 180 pmol/L and creatinine 1.4 mg/dL may need an eGFR review before anyone interprets the marker as gynaecologic. Read more about chronic kidney disease staging before attributing a renal-associated elevation to cancer.
ແຄນເທສຕີ ເປັນ ບໍລິການຕີຄວາມຜົນການກວດຂອງ AI that reads HE4 with creatinine, eGFR, urea and urine findings rather than generating a cancer label from one protein. A falling eGFR alongside a rising HE4 is often a renal signal first, though concerning symptoms or imaging still require separate assessment.
Benign and non-cancer causes of high HE4 levels
High HE4 levels can result from kidney impairment, older age and cigarette smoking, and they may rise in some chronic pulmonary, cardiac or inflammatory conditions. Benign gynaecologic conditions generally affect HE4 less than CA-125, but “less often” does not mean “never.”
Smoking is independently associated with higher HE4 concentrations, so documenting current smoking status is clinically relevant. Age also shifts the expected range upward, especially after menopause. These effects are usually modest compared with severe renal impairment, but they can explain a borderline result around 75 to 110 pmol/L.
Endometriosis, fibroids and menstruation frequently raise CA-125 more than HE4; that difference is one reason clinicians sometimes order both markers. Yet symptoms such as cyclical pelvic pain still deserve a clinical assessment, regardless of a reassuring HE4. Our review of when CA-125 is high covers the overlap and the limits.
Medication lists matter indirectly. Diuretics, SGLT2 medicines and acute illness can change hydration or kidney indices, while lithium can affect renal function over time; see our guide to ການກວດຕິດຕາມ lithium. I would not stop a prescribed medicine because of HE4 without speaking to the prescriber.
How menopause, age and smoking change HE4 interpretation
Menopausal status changes both the expected HE4 range and the way ROMA calculates risk. A 55-year-old who has had no periods for 18 months is not interpreted by the same cutoff logic as a 35-year-old with regular cycles.
Most laboratories define menopause clinically—usually 12 consecutive months without a menstrual period when no other cause is present—not by a single FSH result. Surgical menopause, hormonal contraception and hormone therapy can complicate classification. If the laboratory used the wrong menopausal category, the calculated ROMA risk can be misleading.
A practical example: HE4 of 85 pmol/L may be flagged high against a 70 pmol/L premenopausal threshold but fall below a common 140 pmol/L postmenopausal threshold. That does not make either person “safe” or “unsafe”; it changes the background probability and the appropriate pathway.
Cigarette smoking should be recorded honestly because it can nudge HE4 upward and may avert unnecessary alarm. Menopausal hormone therapy does not reliably explain a high HE4, so I would still check renal function and imaging context. For cycle-related lab variation, our ຄູ່ມືຮໍໂມນສຳລັບແມ່ຍິງ ໃຫ້ພື້ນຖານທີ່ເປັນປະໂຫຍດ.
What the ROMA score can and cannot tell you
ROMA combines HE4, CA-125 and menopausal status to estimate the likelihood that an existing adnexal mass is malignant. It is intended to help triage women already planned for surgery or specialist evaluation, not to screen the general population.
ROMA uses different equations before and after menopause, then reports a percentage risk based on the assay and laboratory. Common manufacturer cutoffs vary; examples include roughly 11% to 13% before menopause and 25% to 30% after menopause. A percentage above a cutoff prompts specialist-level assessment, not a statement that cancer is present.
Moore et al. evaluated ROMA in women with pelvic masses and showed that combining HE4 and CA-125 could help identify women needing gynaecologic-oncology referral (Moore et al., 2011). That evidence does not establish ROMA as a population screening tool, because predictive values collapse when the disease is rare in the tested group.
ແຄນເທສຕີ ເປັນ ແພລດຟອມການຕີຄວາມໝາຍ biomarker ຂອງ AI that can explain a reported ROMA calculation, but it does not calculate a diagnosis or overrule the ordering clinician. For patients already treated for a malignancy, tumour-marker trends after treatment need the same caution: trend is useful only within a defined clinical plan.
Why HE4 or ROMA cannot diagnose ovarian cancer alone
HE4 and ROMA cannot diagnose ovarian cancer because neither test identifies a tumour’s location, cell type or stage. Diagnosis requires synthesis of symptoms, pelvic examination, imaging and, when needed, tissue confirmation after appropriate specialist planning.
A blood marker can be high from impaired clearance, another organ condition or assay variation, while a cancer can produce a normal marker. This bidirectional limitation is exactly why tumour markers are poor standalone tests. The absence of a high HE4 should never delay investigation of a clearly concerning ultrasound.
The U.S. Preventive Services Task Force recommends against screening asymptomatic average-risk women for ovarian cancer with CA-125, ultrasound or other screening strategies because harms from false positives outweigh proven benefit (USPSTF, 2018). HE4 and ROMA do not change that recommendation for average-risk screening.
An elevated HE4 should therefore be framed as a risk-modifying clue, not a verdict. Patients with a strong inherited-risk history may need a separate genetics and prevention discussion; our guide to family history and cancer tests explains what routine blood work cannot provide.
What clinicians usually check after high HE4 test results
After a high HE4 result, clinicians usually verify kidney function, review symptoms and arrange or review pelvic imaging if there is a mass or concerning presentation. The next test is driven by the original reason HE4 was ordered, not by a universal one-size-fits-all algorithm.
A sensible first review includes the laboratory method, HE4 value and date, CA-125, creatinine, eGFR, urinalysis, smoking status, menopausal status, medicines and prior imaging. If renal function has changed quickly, repeat renal testing may be more informative than repeating HE4 immediately. Our ຄູ່ມື basic metabolic panel explains the companion tests.
Transvaginal ultrasound is commonly the first imaging study for an adnexal mass because it assesses morphology, solid areas, septations, fluid and blood flow characteristics. Imaging descriptors and symptoms generally carry more actionable information than a small marker change. MRI or CT is selected by the treating team when ultrasound leaves uncertainty or staging is needed.
As Dr. Thomas Klein, I would ask for a clear written plan: who owns the follow-up, which result will trigger referral and when you will hear back. This is more useful than being told merely to “watch it.”
Symptoms that need faster assessment regardless of the HE4 number
Severe or worsening pelvic or abdominal symptoms need prompt medical assessment even if HE4 is normal. A marker result should never be used to explain away acute pain, increasing abdominal size, vomiting, breathlessness or reduced urine output.
Seek urgent same-day care for sudden severe lower abdominal pain, fainting, persistent vomiting, fever with pelvic pain, new breathlessness, or rapidly enlarging abdominal distension. These symptoms can reflect torsion, obstruction, fluid accumulation, infection, kidney injury or other conditions that require timely examination. They are not specific to cancer.
Book a prompt but non-emergency appointment for bloating or pelvic or abdominal pain occurring more than 12 days per month, early satiety, urinary urgency or unintentional weight loss that persists for several weeks. Frequency and change from your usual baseline matter more than one isolated bad day.
Heavy periods can cause fatigue and iron deficiency while obscuring the broader symptom story; our review of ການເລືອດປະຈຳເດືອນທີ່ອອກຫຼາຍ explains when bleeding itself needs urgent care.
When repeating an HE4 test helps—and when it adds noise
Repeating HE4 is most useful when the first result may have been influenced by acute kidney change, laboratory variation or an unresolved clinical question. It is least useful when repeated without a plan, especially across different laboratories and assay platforms.
If a repeat is planned, use the same laboratory where possible and repeat creatinine and eGFR on the same date. A difference of 10 to 20 pmol/L near a threshold can fall within ordinary biological and analytical variation. A large persistent rise—particularly with stable renal function and changing imaging—carries more weight.
Do not attempt to lower HE4 through detoxes, fasting or supplements before a repeat. These actions can change hydration and creatinine without addressing the underlying question. A well-hydrated routine sample, taken when you are not acutely unwell if clinically safe to wait, is generally more interpretable.
Kantesti’s ການວິເຄາະຫ້ອງທົດລອງຕາມໄລຍະ (longitudinal lab analysis) compares dates and companion markers so that a genuine trajectory is easier to distinguish from a different laboratory’s reference range.
HE4 after ovarian cancer treatment: why your own baseline matters
In people treated for ovarian cancer, HE4 may be followed as one component of surveillance when the treating oncology team has established that it tracked the individual’s disease. A rising result alone still does not prove recurrence or determine treatment.
A useful surveillance marker is one that was elevated before treatment, fell with response and is measured consistently afterward. If HE4 was never elevated at diagnosis, it is unlikely to become a reliable personal recurrence marker. CA-125, symptoms, examination and imaging may be more informative depending on the tumour type.
A single value above the laboratory interval can reflect eGFR decline, infection, fluid shifts or assay change. Oncology teams often confirm an unexpected rise and consider the rate of change before arranging imaging. This avoids treating a laboratory fluctuation rather than a person.
Other tumour markers have similar limitations; compare the logic in our CA 19-9 result guide. Surveillance plans should be agreed with the oncology team, not constructed from online cutoff tables.
How to use an AI explanation of HE4 results safely
An AI explanation is safest when it identifies missing context, explains terminology and flags questions for a clinician rather than declaring cancer risk from an isolated result. It should show its assumptions, including the laboratory range and kidney-function data used.
Kantesti AI interprets HE4 results by checking the reported unit, assay interval, CA-125, creatinine, eGFR and time trend before presenting a patient-friendly explanation. Our system is designed to say when a report lacks the information needed for meaningful interpretation. That restraint is clinically safer than confident pattern-matching.
Before uploading any report, remove unnecessary identifiers and confirm that the optical reading captured decimal points, units and reference intervals correctly. A value of 14.0 versus 140 pmol/L produces an entirely different discussion. Our ກວດສອບຄວາມຖືກຕ້ອງການອັບໂຫຼດ PDF covers common transcription problems.
Kantesti’s វិធីសាស្ត្រធ្វើឲ្យមានសុពលភាពផ្នែកព្យាបាល (clinical validation) describes why AI-generated lab explanations require medical oversight and why urgent symptoms should bypass digital interpretation. A clear explanation can reduce panic; it must not delay care.
Questions to bring to your appointment after a high HE4 result
The best appointment questions establish whether HE4 was ordered for a mass, what your kidney function was that day and what specific follow-up is planned. A focused list often turns an alarming laboratory flag into a manageable clinical conversation.
Ask: “Which HE4 assay and reference range did my laboratory use?” “What were my creatinine and eGFR?” “Was I classified as premenopausal or postmenopausal correctly?” and “Do my symptoms or imaging findings change the concern?” Each question addresses a separate source of false reassurance or false alarm.
Also ask whether a repeat should use the same laboratory, whether CA-125 is clinically appropriate, and whether a gynaecologist or gynaecologic oncologist should review the scan. If you have a family history of ovarian, breast, pancreatic or prostate cancer, ask whether genetic counselling is relevant. The Kantesti ຄະນະກຳມະການທີ່ປຶກສາທາງການແພດ supports our clinician-reviewed standards for these high-stakes interpretation pathways.
As of September 18, 2026, there is no HE4 cutoff that safely substitutes for clinical judgment. The right next step is the one that accounts for your symptoms, renal function, imaging and personal risk—not the one that reacts most strongly to a red flag.
ຄໍາຖາມທີ່ຖາມເລື້ອຍໆ
ລະດັບ HE4 ເທົ່າໃດຈຶ່ງຊີ້ບອກວ່າເປັນມະເຮັງຮັງໄຂ່?
ບໍ່ມີລະດັບ HE4 ໃດ ທີ່ຊີ້ບອກເຖິງມະເຮັງຮວຍໄຂ່ໄດ້ຢ່າງແນ່ນອນ. ການຕັດສິນໃຈທົ່ວໄປຂອງການວິເຄາະແມ່ນປະມານ 70 pmol/L ກ່ອນໝົດປະຈຳເດືອນ ແລະ 140 pmol/L ຫຼັງໝົດປະຈຳເດືອນ, ແຕ່ການເຮັດວຽກຂອງໝາກໄຂ່ຫຼັງທີ່ຜິດປົກກະຕິສາມາດເຮັດໃຫ້ HE4 ສູງກວ່າຄ່າເຫຼົ່ານີ້ໄດ້ໂດຍບໍ່ມີມະເຮັງ. ຄ່າທີ່ສູງກວ່າ 300 pmol/L ໂດຍທົ່ວໄປແລ້ວແມ່ນຮຽກຮ້ອງໃຫ້ມີການປະເມີນໂດຍຜູ້ຊ່ຽວຊານຢ່າງຮີບດ່ວນ, ໂດຍສະເພາະກັບກ້າມເນື້ອໃນກະດູກກະດູກສັນຫຼັງທີ່ໜ້າສົງໄສ, ແຕ່ຍັງຄົງບໍ່ສາມາດວິນິດໄສໄດ້. ການຖ່າຍຮູບ ແລະ ການປະເມີນທາງຄລີນິກຈະເປັນໂຕກຳນົດວ່າເປັນມະເຮັງຫຼືບໍ່.
ພະຍາດຫມາກໄຂ່ຫຼັງເຮັດໃຫ້ລະດັບ HE4 ສູງຂຶ້ນໄດ້ບໍ?
ແມ່ນແລ້ວ, ພະຍາດໝາກໄຂ່ຫຼັງຊໍາເຮື້ອສາມາດເຮັດໃຫ້ລະດັບ HE4 ສູງຂຶ້ນຫຼາຍໄດ້ ເພາະການກັ່ນຕອງທີ່ຫຼຸດລົງເຮັດໃຫ້ການຊໍາລະລ້າງ HE4 ຫຼຸດລົງ. eGFR ຕ່ຳກວ່າ 60 mL/min/1.73 m² ສາມາດສົ່ງຜົນກະທົບຢ່າງຫຼວງຫຼາຍຕໍ່ການຕີຄວາມໝາຍ, ແລະການບົກຜ່ອງຂອງໝາກໄຂ່ຫຼັງຂັ້ນສູງອາດເຮັດໃຫ້ຄ່າ HE4 ຢູ່ໃນຮ້ອຍ pmol/L ໂດຍບໍ່ມີມະເຮັງຮວຍໄຂ່. Creatinine ແລະ eGFR ຄວນໄດ້ຮັບການກວດສອບໃນວັນດຽວກັນກັບຜົນ HE4. ຜົນ HE4 ທີ່ສູງບໍ່ຄວນຖືກຕີຄວາມໝາຍໂດຍບໍ່ຄໍານຶງເຖິງການເຮັດວຽກຂອງໝາກໄຂ່ຫຼັງ.
ລະດັບ HE4 ປົກກະຕິສຳລັບແມ່ຍິງຫຼັງໝົດປະຈຳເດືອນແມ່ນເທົ່າໃດ?
ເຄິ່ງໜຶ່ງຂອງຄ່າ HE4 ທີ່ໃຊ້ຫຼາຍທີ່ສຸດສຳລັບແມ່ຍິງຫຼັງໝົດປະຈຳເດືອນແມ່ນ 140 pmol/L, ເຖິງວ່າໄລຍະອ້າງອີງທີ່ຖືກຕ້ອງແມ່ນໄລຍະທີ່ພິມໂດຍຫ້ອງທົດລອງທີ່ໄດ້ດຳເນີນການວິເຄາະ. ອາຍຸ, ສະຖານະການສູບຢາ ແລະ ໂດຍສະເພາະການເຮັດວຽກຂອງໝາກໄຂ່ຫຼັງສາມາດປ່ຽນແປງຄ່າທີ່ຄາດຫວັງໄດ້. ຜົນໄດ້ຮັບຕ່ຳກວ່າ 140 pmol/L ບໍ່ໄດ້ຕັດໂອກາດເປັນມະເຮັງຮັງໄຂ່, ແລະຜົນໄດ້ຮັບສູງກວ່າ 140 pmol/L ບໍ່ໄດ້ວິນິດໄສມັນ. ຜົນໄດ້ຮັບມີປະໂຫຍດຫຼາຍທີ່ສຸດເມື່ອຈັບຄູ່ກັບຜົນການອົບອົບສຽງ ແລະ CA-125 ບ່ອນທີ່ເໝາະສົມທາງດ້ານຄລີນິກ.
Can ROMA diagnose ovarian cancer?
No, ROMA cannot diagnose ovarian cancer. ROMA combines HE4, CA-125 and menopausal status to estimate the risk that an existing adnexal mass is malignant, usually to support referral and surgical planning. Common ROMA thresholds vary by assay and menopausal status, often around 11% to 13% before menopause and 25% to 30% after menopause. It is not validated as a screening test for people without a pelvic mass or symptoms.
Can endometriosis raise HE4?
Endometriosis can occasionally be associated with an elevated HE4 result, although CA-125 is more commonly elevated in endometriosis than HE4. A normal HE4 does not exclude endometriosis, and a mildly high HE4 does not establish ovarian cancer. Kidney function, smoking, age and imaging often explain the result better than endometriosis alone. Persistent pelvic pain, painful periods or fertility concerns deserve gynaecologic review regardless of marker results.
Should I repeat a high HE4 test?
Repeating a high HE4 test can help when kidney function was changing, the sample was taken during acute illness, or the result conflicts with the clinical picture. Repeat testing should ideally use the same laboratory and include creatinine and eGFR on the same day. A 10 to 20 pmol/L difference near a cutoff may reflect ordinary variation, whereas a sustained rise with stable renal function deserves more attention. Your clinician should specify what decision the repeat result is intended to inform.
ຮັບການວິເຄາະຜົນກວດເລືອດດ້ວຍ AI ທັນທີ
ເຂົ້າຮ່ວມຜູ້ໃຊ້ຫຼາຍກວ່າ 2 ລ້ານຄົນທົ່ວໂລກ ທີ່ໄວ້ໃຈ Kantesti ສຳລັບການວິເຄາະການກວດເລືອດທີ່ທັນທີ ແລະຖືກຕ້ອງ. ອັບໂຫຼດຜົນກວດເລືອດຂອງທ່ານ ແລະຮັບການຕີຄວາມໝາຍຢ່າງຄົບຖ້ວນຂອງ biomarker 15,000+ ໃນວິນາທີ.
📚 ບົດຄວາມວິຈັຍທີ່ອ້າງອີງ
Klein, T., Mitchell, S., & Weber, H. (2026). Urobilinogen ໃນການກວດຍ່ຽວ: ຄູ່ມືການກວດຍ່ຽວຄົບຖ້ວນ 2026. ການຄົ້ນຄວ້າທາງການແພດຂອງ AI Kantesti.
Klein, T., Mitchell, S., & Weber, H. (2026). ຄູ່ມືການສຶກສາທາດເຫຼັກ: TIBC, ຄວາມອີ່ມຕົວຂອງທາດເຫຼັກ ແລະ ຄວາມສາມາດໃນການຜູກມັດ. ການຄົ້ນຄວ້າທາງການແພດຂອງ AI Kantesti.
📖 ເອກະສານອ້າງອີງທາງການແພດພາຍນອກ
ACOG Committee on Practice Bulletins—Gynecology (2016). Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstetrics & Gynecology.
⚕️ ຂໍ້ສັງເກດທາງການແພດ
ບົດຄວາມນີ້ມີຈຸດປະສົງເພື່ອການສຶກສາເທົ່ານັ້ນ ແລະບໍ່ແມ່ນຄຳແນະນຳທາງການແພດ. ຄວນປຶກສາຜູ້ໃຫ້ບໍລິການດ້ານສຸຂະພາບທີ່ມີຄຸນວຸດທິສະເໝີ ສຳລັບການວິນິດໄຊ ແລະ ການຕັດສິນໃຈດ້ານການຮັກສາ.
ສັນຍານຄວາມໄວ້ໃຈ E-E-A-T
ປະສົບການ
ການທົບທວນຄລີນິກຂອງແພດຜູ້ນຳພາ ກ່ຽວກັບຂັ້ນຕອນການຕີຄວາມໝາຍຜົນການກວດໃນຫ້ອງທົດລອງ.
ຄວາມຊ່ຽວຊານ
ວິຊາການແພດທົດລອງ (ການແພດທາງຫ້ອງທົດລອງ) ເນັ້ນໃສ່ວ່າຕົວຊີ້ວັດ (biomarkers) ມີພຶດຕິກຳແນວໃດໃນບັນບົດທາງຄລີນິກ.
ຄວາມເປັນອຳນາດ
ຂຽນໂດຍທ່ານດຣ. Thomas Klein ໂດຍມີການກວດທານໂດຍທ່ານດຣ. Sarah Mitchell ແລະ ສາດສະດາຈານດຣ. Hans Weber.
ຄວາມໜ້າເຊື່ອຖື
ການຕີຄວາມໝາຍອີງຕາມຫຼັກຖານດ້ວຍເສັ້ນທາງຕິດຕາມທີ່ຊັດເຈນ ເພື່ອຫຼຸດການຕົກໃຈ.